Objective: To assess the efficacy of Docetaxel and Carboplatin combination regimen in non-small cell lung cancer stage IIIB-IV. Patients and Methods: Sixty-five patients with non-small cell lung cancer stage IIIB-IV which had been treated with Docetacel and Carboplatin combination regimen between September 2009 and January 2014 at National Cancer Hospital and Hanoi Medical University Hospital, were retrospectively investigated. Result: Overall response rate was 41,5 percent, complete response rate and partial response rate was 1,5 percent and 40 percent of patients, respectively. The overall response rate (RR) of group had been treated with 6 courses or more was 63 percent, higher than patients treated with under 6 courses with 26,3 percent., p= 0,007. RR of stage IIIB was 46,4 percent, higher than stage IV with 37,8 percent, the different was no statistically significant with p = 0,659.There was no different between pathology types with p = 0.939. RR of Patients aged 60 years or younger, male, KPS score 80-90 percent and no metastasis was higher than patients over 60 years, female, KPS score 70 percent and metastasis, but this different was no statistically significant. Conclusions: Docetaxel and Carboplatin combination regimen was effective in patients non small cell lung cancer stage IIIB-IV.
- Đăng nhập để gửi ý kiến